Altimmune Secures $100 Million Credit Facility

Altimmune ( (ALT) ) just unveiled an announcement.

On May 13, 2025, Altimmune entered into a Loan and Security Agreement with Hercules Capital, securing a $100 million credit facility to enhance its financial flexibility and support the development of its lead therapeutic candidate, pemvidutide. The company announced its first quarter 2025 financial results, reporting cash and short-term investments of $150 million as of March 31, 2025. Altimmune anticipates significant milestones in 2025, including top-line data from the IMPACT Phase 2b trial of pemvidutide in MASH, and the initiation of Phase 2 trials for AUD and ALD. These developments are expected to strengthen Altimmune’s position in the biopharmaceutical industry, particularly in addressing unmet medical needs in liver and cardiometabolic diseases.

The most recent analyst rating on (ALT) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.

Spark’s Take on ALT Stock

According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.

Altimmune’s strong balance sheet and promising clinical pipeline are positive, but challenges remain with profitability and cash flow. Technical indicators are neutral, while the earnings call provides some optimism for future growth.

To see Spark’s full report on ALT stock, click here.

More about Altimmune

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD).

Average Trading Volume: 2,610,967

Technical Sentiment Signal: Sell

Current Market Cap: $462.9M

See more data about ALT stock on TipRanks’ Stock Analysis page.